

# Michael R Jacobs

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4423950/publications.pdf>

Version: 2024-02-01

92  
papers

4,034  
citations

101543

36  
h-index

128289

60  
g-index

97  
all docs

97  
docs citations

97  
times ranked

3888  
citing authors

#	ARTICLE	IF	CITATIONS
1	Accuracy of Direct Antimicrobial Susceptibility Testing of Gram-Negative Bacteria from Positive Blood Cultures Using MicroScan System and Value of Using Expert Rules for $\beta$ -Lactam Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, aac0214821.	3.2	2
2	Multicenter Evaluation of the Acuitas $\hat{A}$ ® AMR Gene Panel for Detection of an Extended Panel of Antimicrobial Resistance Genes among Bacterial Isolates. <i>Journal of Clinical Microbiology</i> , 2022, , JCM0209821.	3.9	2
3	Genomic heterogeneity underlies multidrug resistance in <i>Pseudomonas aeruginosa</i> : A population-level analysis beyond susceptibility testing. <i>PLoS ONE</i> , 2022, 17, e0265129.	2.5	13
4	Imipenem/Relebactam Resistance in Clinical Isolates of Extensively Drug Resistant <i>Pseudomonas aeruginosa</i> : Inhibitor-Resistant $\beta$ -Lactamases and Their Increasing Importance. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0179021.	3.2	8
5	<i>Parabacteroides distasonis</i> : intriguing aerotolerant gut anaerobe with emerging antimicrobial resistance and pathogenic and probiotic roles in human health. <i>Gut Microbes</i> , 2021, 13, 1922241.	9.8	139
6	Recent advances in rapid antimicrobial susceptibility testing systems. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 563-578.	3.1	6
7	Detection of <i>mcr-1</i> gene in a clinical <i>Escherichia coli</i> strain in North Carolina: first report. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 25, 154-156.	2.2	1
8	A $\beta$ -lactam siderophore antibiotic effective against multidrug-resistant <i>Pseudomonas aeruginosa</i> , <i>Klebsiella pneumoniae</i> , and <i>Acinetobacter</i> spp.. <i>European Journal of Medicinal Chemistry</i> , 2021, 220, 113436.	5.5	14
9	A two-part phase 1 study to establish and compare the safety and local tolerability of two nasal formulations of XF-73 for decolonisation of <i>Staphylococcus aureus</i> : A previously investigated 0.5 mg/g viscosified gel formulation versus a modified formulation. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 21, 171-180.	2.2	12
10	Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant <i>Enterobacter</i> sp. Carrying Both <i>Klebsiella pneumoniae</i> Carbapenemase-4 and New Delhi Metallo- $\beta$ -Lactamase-1. <i>Clinical Infectious Diseases</i> , 2020, 71, 1095-1098.	5.8	59
11	AbGRI4, a novel antibiotic resistance island in multiply antibiotic-resistant <i>Acinetobacter baumannii</i> clinical isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2760-2768.	3.0	18
12	Bacterial contamination and septic transfusion reaction rates associated with platelet components before and after introduction of primary culture: experience at a US Academic Medical Center 1991 through 2017. <i>Transfusion</i> , 2020, 60, 974-985.	1.6	16
13	A $\beta$ -Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 5990-6002.	6.4	20
14	ARGONAUT II Study of the <i>In Vitro</i> Activity of Plazomicin against Carbapenemase-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	11
15	Review of current transfusion therapy and blood banking practices. <i>Blood Reviews</i> , 2019, 38, 100593.	5.7	49
16	Association of Laboratory Methods, Colonization Density, and Age With Detection of <i>Streptococcus pneumoniae</i> in the Nasopharynx. <i>American Journal of Epidemiology</i> , 2019, 188, 2110-2119.	3.4	14
17	Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Producing KPC. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	26
18	Targeting Multidrug-Resistant <i>Acinetobacter</i> spp.: Sulbactam and the Diazabicyclooctenone $\beta$ -Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent. <i>MBio</i> , 2019, 10, .	4.1	64

#	ARTICLE	IF	CITATIONS
19	Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent $\beta$ -Lactamase Inhibitor Combination. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	65
20	Rapid Replacement of <i>Acinetobacter baumannii</i> Strains Accompanied by Changes in Lipooligosaccharide Loci and Resistance Gene Repertoire. <i>MBio</i> , 2019, 10, .	4.1	28
21	Complete Genome Sequence of a <i>Parabacteroides distasonis</i> Strain (CavFT hAR46) Isolated from a Gut Wall-Cavitating Microlesion in a Patient with Severe Crohn's Disease. <i>Microbiology Resource Announcements</i> , 2019, 8, .	0.6	22
22	ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and <i>Enterobacteriaceae</i> with Defined Extended-Spectrum $\beta$ -Lactamases and Carbapenemases. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	81
23	Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against <i>Pseudomonas aeruginosa</i> : PRIMERS IV. <i>Clinical Infectious Diseases</i> , 2019, 68, 1823-1830.	5.8	37
24	Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using $\beta$ -Lactamase Inhibitors and $\beta$ -Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 4067-4086.	6.4	117
25	Prolonged Course of Salmonella Pelvic Osteomyelitis in an Immunocompetent African American Child: A Case Report and Review of the Literature. <i>Journal of Pediatric Infectious Diseases</i> , 2018, 13, 084-088.	0.2	1
26	Emergence of Resistance to Colistin During the Treatment of Bloodstream Infection Caused by <i>Klebsiella pneumoniae</i> Carbapenemase-Producing <i>Klebsiella pneumoniae</i> . <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy054.	0.9	11
27	Transcriptome Remodeling of <i>Acinetobacter baumannii</i> during Infection and Treatment. <i>MBio</i> , 2017, 8, .	4.1	53
28	Can Ceftazidime-Avibactam and Aztreonam Overcome $\beta$ -Lactam Resistance Conferred by Metallo- $\beta$ -Lactamases in <i>Enterobacteriaceae</i> ?. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	217
29	Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant <i>Enterobacteriaceae</i> (CRE) in the CRE Epicenter of the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	178
30	Multicenter Clinical Evaluation of BacT/Alert Virtuo Blood Culture System. <i>Journal of Clinical Microbiology</i> , 2017, 55, 2413-2421.	3.9	42
31	Nosocomial Outbreak of Extensively Drug-Resistant <i>Acinetobacter baumannii</i> Isolates Containing <i>bla</i> <sub>OXA-237</sub> Carried on a Plasmid. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	38
32	Failure to Communicate: Transmission of Extensively Drug-Resistant <i>bla</i> <sub>OXA-237</sub> -Containing <i>Acinetobacter baumannii</i> Multiple Facilities in Oregon, 2012-2014. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 1335-1341.	1.8	17
33	Avibactam Restores the Susceptibility of Clinical Isolates of <i>Stenotrophomonas maltophilia</i> to Aztreonam. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	52
34	Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against <i>Acinetobacter</i> spp. in PRIMERS III. <i>Journal of Clinical Microbiology</i> , 2017, 55, 134-144.	3.9	26
35	AAI101, a Novel $\beta$ -Lactamase Inhibitor: Microbiological and Enzymatic Profiling. <i>Open Forum Infectious Diseases</i> , 2017, 4, S375-S375.	0.9	7
36	Benefit-risk Evaluation for Diagnostics: A Framework (BED-FRAME). <i>Clinical Infectious Diseases</i> , 2016, 63, 812-817.	5.8	27

#	ARTICLE	IF	CITATIONS
37	The Changing Role of the Clinical Microbiology Laboratory in Defining Resistance in Gram-negatives. <i>Infectious Disease Clinics of North America</i> , 2016, 30, 323-345.	5.1	12
38	Molecular Diversity and Plasmid Analysis of KPC-Producing <i>Escherichia coli</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4073-4081.	3.2	33
39	Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance. <i>Blood</i> , 2016, 127, 496-502.	1.4	165
40	Whole-Genome Comparative Analysis of Two Carbapenem-Resistant ST-258 <i>Klebsiella pneumoniae</i> Strains Isolated during a North-Eastern Ohio Outbreak: Differences within the High Heterogeneity Zones. <i>Genome Biology and Evolution</i> , 2016, 8, 2036-2043.	2.5	28
41	Activity of nitazoxanide and tizoxanide against <i>Mycobacterium tuberculosis</i> in vitro and in whole blood culture. <i>Tuberculosis</i> , 2016, 98, 92-96.	1.9	17
42	Genome dynamics of multidrug-resistant <i>Acinetobacter baumannii</i> during infection and treatment. <i>Genome Medicine</i> , 2016, 8, 26.	8.2	77
43	Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II. <i>Clinical Infectious Diseases</i> , 2016, 62, 181-189.	5.8	52
44	Methylfolate Trap Promotes Bacterial Thymineless Death by Sulfa Drugs. <i>PLoS Pathogens</i> , 2016, 12, e1005949.	4.7	42
45	Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic <i>Escherichia coli</i> strains expressing selected single $\beta$ -lactamases. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 82, 65-69.	1.8	38
46	Complete Sequence of a <i>bla</i> <sub>KPC</sub> -Harboring Cointegrate Plasmid Isolated from <i>Escherichia coli</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2956-2959.	3.2	23
47	Community-Acquired Pyelonephritis in Pregnancy Caused by KPC-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4375-4378.	3.2	24
48	SISPA-Seq for rapid whole genome surveys of bacterial isolates. <i>Infection, Genetics and Evolution</i> , 2015, 32, 191-198.	2.3	16
49	Sulfamethoxazole Susceptibility of <i>Mycobacterium tuberculosis</i> Isolates from HIV-Infected Ugandan Adults with Tuberculosis Taking Trimethoprim-Sulfamethoxazole Prophylaxis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5844-5846.	3.2	6
50	Surveillance of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> : Tracking Molecular Epidemiology and Outcomes through a Regional Network. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4035-4041.	3.2	132
51	Identification of Occult <i>Fusobacterium nucleatum</i> Central Nervous System Infection by Use of PCR-Electrospray Ionization Mass Spectrometry. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3462-3464.	3.9	9
52	Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> Isolates Containing <i>bla</i> <sub>VIM-2</sub> and Elements of <i>Salmonella</i> Genomic Island 2: a New Genetic Resistance Determinant in Northeast Ohio. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5929-5935.	3.2	34
53	Serotype distribution and antimicrobial susceptibility of USA <i>Streptococcus pneumoniae</i> isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 80, 19-25.	1.8	45
54	Detection of bacterial contamination in prestorage culture-negative apheresis platelets on day of issue with the Pan Genera Detection test. <i>Transfusion</i> , 2011, 51, 2573-2582.	1.6	119

#	ARTICLE	IF	CITATIONS
55	Changes in Serotypes and Antimicrobial Susceptibility of Invasive <i>Streptococcus pneumoniae</i> Strains in Cleveland: a Quarter Century of Experience. <i>Journal of Clinical Microbiology</i> , 2008, 46, 982-990.	3.9	71
56	Relationship between Bacterial Load, Species Virulence, and Transfusion Reaction with Transfusion of Bacterially Contaminated Platelets. <i>Clinical Infectious Diseases</i> , 2008, 46, 1214-1220.	5.8	156
57	Oral $\beta$ -lactams applied to uncomplicated infections of skin and skin structures. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 57, S55-S65.	1.8	24
58	Nasopharyngeal Carriage of Respiratory Pathogens in Children Undergoing Pressure Equalization Tube Placement in the Era of Pneumococcal Protein Conjugate Vaccine Use. <i>Laryngoscope</i> , 2007, 117, 295-298.	2.0	19
59	Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1957-1966.	1.8	38
60	Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital, 1991 through 2004. <i>Transfusion</i> , 2006, 46, 719-730.	1.6	84
61	Enhancement of a culture-based bacterial detection system (eBDS) for platelet products based on measurement of oxygen consumption. <i>Transfusion</i> , 2005, 45, 984-993.	1.6	40
62	Extended release amoxicillin/clavulanate: optimizing a product for respiratory infections based on pharmacodynamic principles. <i>Expert Review of Anti-Infective Therapy</i> , 2005, 3, 353-360.	4.4	3
63	Fluoroquinolones as Chemotherapeutics Against Mycobacterial Infections. <i>Current Pharmaceutical Design</i> , 2004, 10, 3213-3220.	1.9	33
64	In Vitro Activity of the New Quinolone WCK 771 against Staphylococci. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3338-3342.	3.2	42
65	<i>Streptococcus pneumoniae</i> : Epidemiology and patterns of resistance. <i>The American Journal of Medicine: Supplement</i> , 2004, 117, 3-15.	1.6	47
66	Susceptibility of <i>Streptococcus pneumoniae</i> , <i>Haemophilus influenzae</i> , and <i>Moraxella catarrhalis</i> to 17 oral antimicrobial agents based on pharmacodynamic parameters: 1998-2001 U.S. Surveillance Study. <i>Clinics in Laboratory Medicine</i> , 2004, 24, 503-530.	1.4	48
67	Mechanisms of resistance among respiratory tract pathogens. <i>Clinics in Laboratory Medicine</i> , 2004, 24, 419-453.	1.4	10
68	Antimicrobial resistance among pediatric respiratory tract infections: clinical challenges. <i>Seminars in Pediatric Infectious Diseases</i> , 2004, 15, 5-20.	1.7	25
69	The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 229-246.	3.0	417
70	Telithromycin post-antibiotic and post-antibiotic sub-MIC effects for 10 Gram-positive cocci. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 809-812.	3.0	24
71	Macrolide resistance: an increasing concern for treatment failure in children. <i>Pediatric Infectious Disease Journal</i> , 2003, 22, S131-S138.	2.0	53
72	Effects of Various Test Media on the Activities of 21 Antimicrobial Agents against <i>Haemophilus influenzae</i> . <i>Journal of Clinical Microbiology</i> , 2002, 40, 3269-3276.	3.9	15

#	ARTICLE	IF	CITATIONS
73	Prevention of otitis media: Role of pneumococcal conjugate vaccines in reducing incidence and antibiotic resistance. <i>Journal of Pediatrics</i> , 2002, 141, 287-293.	1.8	14
74	Release of complement regulatory proteins from ocular surface cells in infections. <i>Current Eye Research</i> , 2000, 21, 856-866.	1.5	18
75	Evaluation of Etest for Susceptibility Testing of <i>Mycobacterium tuberculosis</i> . <i>Journal of Clinical Microbiology</i> , 2000, 38, 3834-3836.	3.9	21
76	Activity of HMR 3647 Compared to Those of Six Compounds against 235 Strains of <i>Enterococcus faecalis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 166-168.	3.2	12
77	<i>Streptococcus pneumoniae</i> : Activity of newer agents against penicillin-resistant strains. <i>Current Infectious Disease Reports</i> , 1999, 1, 13-21.	3.0	6
78	Activity of Quinolones Against <i>Mycobacteria</i> . <i>Drugs</i> , 1999, 58, 19-22.	10.9	48
79	Antianaerobic Activity of Gatifloxacin. <i>Drugs</i> , 1999, 58, 113-116.	10.9	1
80	Clinafloxacin Antibacterial Activity. <i>Drugs</i> , 1999, 58, 217-221.	10.9	3
81	Levofloxacin and Clarithromycin Antipneumococcal Activity. <i>Drugs</i> , 1999, 58, 366-368.	10.9	0
82	Antipneumococcal Activity of Gatifloxacin by Time-Kill Methodology. <i>Drugs</i> , 1999, 58, 369-371.	10.9	0
83	Antipneumococcal Activity of Gatifloxacin by Agar Dilution MIC. <i>Drugs</i> , 1999, 58, 372-373.	10.9	0
84	Postantibiotic Effect of Levofloxacin Against <i>Pneumococci</i> . <i>Drugs</i> , 1999, 58, 378-380.	10.9	2
85	Adhesion of <i>Staphylococcus epidermidis</i> to biomedical polymers: Contributions of surface thermodynamics and hemodynamic shear conditions. <i>Journal of Biomedical Materials Research Part B</i> , 1995, 29, 485-493.	3.1	66
86	Activity of CP 99, 219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosylfloxacin, sparfloxacin and grepaloxacin against penicillin-susceptible and -resistant pneumococci. <i>Journal of Antimicrobial Chemotherapy</i> , 1995, 35, 230-232.	3.0	108
87	Activity of Quinolones against <i>Mycobacteria</i> . <i>Drugs</i> , 1995, 49, 67-75.	10.9	25
88	Antimicrobial activity and in vitro corneal epithelial toxicity of antimicrobial agents for Gram-positive corneal pathogens. <i>Current Eye Research</i> , 1993, 12, 603-608.	1.5	8
89	<i>Corynebacterium striatum</i> : A Diphtheroid with Pathogenic Potential. <i>Clinical Infectious Diseases</i> , 1993, 17, 21-25.	5.8	67
90	Topical fluoroquinolones: Antimicrobial activity and in vitro corneal epithelial toxicity. <i>Current Eye Research</i> , 1991, 10, 557-563.	1.5	51

#	ARTICLE	IF	CITATIONS
91	Prevalence and significance of methicillin-resistant staphylococcus aureus in patients with cystic fibrosis. Pediatric Pulmonology, 1988, 4, 159-163.	2.0	54
92	Synergy of amoxicillin combined with clavulanate and YTR 830 in experimental infections in mice. Journal of Antimicrobial Chemotherapy, 1986, 18, 271-276.	3.0	14